{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T10:54:42Z","timestamp":1792925682801,"version":"4.5.0"},"reference-count":12,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"42","license":[{"start":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T00:00:00Z","timestamp":1666310400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,10,21]]},"abstract":"<jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Eptifibatide is an antiplatelet agent used in the medical management of acute coronary syndrome. Although multiple studies did not reveal a significant association between eptifibatide and the development of thrombocytopenia, recent case reports brought attention to this relatively rare side effect.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>We report a 61 years old male with acute coronary syndrome who underwent primary coronary intervention.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnosis and intervention:<\/jats:title>\n            <jats:p>The patient developed acute profound thrombocytopenia following eptifibatide administration. Following prompt offending drug discontinuation, the platelet counts recovered, without clinical sequelae or the need for platelet transfusion. Dual antiplatelet therapy with aspirin and clopidogrel was resumed after platelet count normalization.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>The patient had a normal platelet count and no bleeding events on follow-up after three months upon discharge.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Eptifibatide, a glycoprotein IIa\/IIIb inhibitor used in the management of acute coronary syndrome, can induce acute, profound thrombocytopenia that can have significant morbidity in patients. This case highlights this relatively rare side effect and the importance of monitoring blood counts and observing for any signs of bleeding or thrombosis that might occur in such patients.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000028243","type":"journal-article","created":{"date-parts":[[2022,10,24]],"date-time":"2022-10-24T19:02:31Z","timestamp":1666638151000},"page":"e28243","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Eptifibatide-induced acute profound thrombocytopenia: A case report"],"prefix":"10.1097","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2231-7546","authenticated-orcid":false,"given":"Mohammed A.","family":"Alamin","sequence":"first","affiliation":[{"name":"Hamad General Hospital, Internal Medicine Department, Hamad Medical Corporation, Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulrahman","family":"Al-Mashdali","sequence":"additional","affiliation":[{"name":"Hamad General Hospital, Internal Medicine Department, Hamad Medical Corporation, Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawoud I.","family":"Al Kindi","sequence":"additional","affiliation":[{"name":"Department of Adult Cardiology, Heart Hospital, Hamad Medical Corporation, Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elkhansa A.","family":"Elshaikh","sequence":"additional","affiliation":[{"name":"Othman Digna Hospital, Port-Sudan, Sudan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahmi","family":"Othman","sequence":"additional","affiliation":[{"name":"Department of Adult Cardiology, Heart Hospital, Hamad Medical Corporation, Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1056\/NEJM199808133390704","article-title":"Inhibition of platelet glycoprotein IIb\/IIIa with eptifibatide in patients with acute coronary syndromes.","volume":"339","year":"1998","journal-title":"N Engl J Med"},{"key":"R2-20250504","first-page":"1422","article-title":"Integrilin to minimise platelet aggregation and coronary thrombosis-II.","volume":"349","year":"1997","journal-title":"Lancet"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1016\/S0140-6736(00)03400-0","article-title":"Enhanced suppression of the platelet IIb\/IIIa receptor with integrilin therapy. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial.","volume":"356","year":"2000","journal-title":"Lancet"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ahj.2005.04.005","article-title":"Facilitated percutaneous coronary intervention for acute ST-segment elevation myocardial infarction: results from the prematurely terminated ADdressing the value of facilitated ANgioplasty after combination therapy or eptifibatide monotherapy in acute myocardial infarction (ADVANCE MI) trial.","volume":"150","year":"2005","journal-title":"Am Heart J"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"m4760","DOI":"10.1136\/bmj.m4760","article-title":"Guideline committee. Acute coronary syndromes: summary of updated NICE guidance.","volume":"372","author":"Corbett","year":"2021","journal-title":"BMJ"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00392-006-0459-7","article-title":"Glycoprotein IIb\/IIIa inhibitor-induced thrombocytopenia: diagnosis and treatment.","volume":"96","author":"Said","year":"2007","journal-title":"Clin Res Cardiol"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1067\/mhj.2000.107554","article-title":"Thrombocytopenia complicating treatment with intravenous glycoprotein IIb\/IIIa receptor inhibitors: a pooled analysis.","volume":"140","author":"Dasgupta","year":"2000","journal-title":"Am Heart J"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/1756-0500-7-107","article-title":"Eptifibatide-induced acute profound thrombocytopenia: a case report.","volume":"7","author":"Graidis","year":"2014","journal-title":"BMC Res Notes"},{"key":"R9-20250504","first-page":"86","article-title":"Eptifibatide-induced thrombocytopenia: with thrombosis and disseminated intravascular coagulation immediately after left main coronary artery percutaneous coronary angioplasty.","volume":"39","author":"Tempelhof","year":"2012","journal-title":"Tex Heart Inst J"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.amjcard.2003.10.041","article-title":"Incidence and time course of thrombocytopenia with abciximab and eptifibatide in patients undergoing percutaneous coronary intervention.","volume":"93","author":"Fahdi","year":"2004","journal-title":"Am J Cardiol"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"340S","DOI":"10.1378\/chest.08-0677","article-title":"Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians evidence-based clinical practice guidelines.","volume":"133","author":"Warkentin","year":"2008","journal-title":"Chest"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.jacc.2007.04.093","article-title":"Two mechanistic pathways for thienopyridine-associated thrombotic thrombocytopenic purpura: a report from the SERF-TTP Research Group and the RADAR Project.","volume":"50","author":"Bennett","year":"2007","journal-title":"J Am Coll Cardiol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000028243","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T04:41:43Z","timestamp":1746333703000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000028243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,21]]},"references-count":12,"journal-issue":{"issue":"42","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000028243","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,21]]}}}